A dose response study with bacampicillin in uncomplicated gonorrhoea

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Neisseria gonorrhoeae causes gonorrhea, a prevalent sexually transmitted infection.
• Antimicrobial resistance in N. gonorrhoeae necessitates evaluating effective treatment regimens.
• Bacampicillin, an oral penicillin derivative, offers a potential therapeutic option.

Purpose of the Study:

• To determine the optimal dose-response relationship of oral bacampicillin combined with probenecid for uncomplicated gonorrhea.
• To evaluate the efficacy and tolerability of different bacampicillin dosages.
• To assess treatment outcomes based on gonococcal susceptibility to ampicillin.

Main Methods:

• A systematic study involving 883 patients with uncomplicated gonorrhea.
• Administration of single oral doses of bacampicillin (400, 800, or 1600 mg) concurrently with 1 g probenecid.
• Monitoring cure rates and adverse events across different dosage groups.

Main Results:

• A single dose of 800 mg bacampicillin plus probenecid was the minimum effective dose for ampicillin-sensitive strains.
• 1600 mg bacampicillin was required for >95% cure rate in patients with reduced ampicillin-sensitive strains.
• Bacampicillin was well tolerated, with loose stools being the most common side effect (1.9%), considered clinically insignificant.

Conclusions:

• The minimum effective dose of bacampicillin and probenecid depends on gonococcal ampicillin sensitivity.
• Higher bacampicillin doses are necessary for strains exhibiting reduced sensitivity.
• Bacampicillin demonstrates a favorable safety profile for gonorrhea treatment.